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Abstract: The process of atherosclerosis leads to the formation of plaques in the arterial wall, resulting
in a decreased blood supply to tissues and organs and its sequelae: morbidity and mortality. A class
of membrane-bound proteins termed scavenger receptors (SRs) are closely linked to the initiation and
progression of atherosclerosis. Increasing interest in understanding SR structure and function has
led to the idea that these proteins could provide new routes for cardiovascular disease diagnosis,
management, and treatment. In this review, we consider the main classes of SRs that are implicated in
arterial disease. We consider how our understanding of SR-mediated recognition of diverse ligands,
including modified lipid particles, lipids, and carbohydrates, has enabled us to better target SR-linked
functionality in disease. We also link clinical studies on vascular disease to our current understanding
of SR biology and highlight potential areas that are relevant to cardiovascular disease management
and therapy.
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1. Introduction
1.1. Oxidized Low-Density Lipoprotein and Atherogenesis
Atherosclerosis is the main biological process underlying cardiovascular disease (CVD)
development and pathology [1]. Atherosclerosis is a multifactorial, progressive, and chronic
inflammatory process characterized by the accumulation of lipid and fibrous elements within the
arterial wall, manifesting macroscopically as an atherosclerotic plaque (Figure 1). The key events
in atherosclerotic plaque initiation and progression are depicted in Figure 1. Atherosclerosis is
initiated by abnormally high circulating blood low-density lipoprotein (LDL) levels (LDL-cholesterol
>40 mg/dL) [2], leading to LDL accumulation within the sub-endothelial matrix of arterial blood
vessel walls, usually operating at a higher blood pressure of 80–120 mm Hg [3]. The LDL deposits
within arterial vessel walls become chemically modified by free radicals produced by vascular cells,
such as the endothelium, vascular smooth muscle, and infiltrating immune cells. These new lipid
particle species are termed minimally modified LDL (mmLDL), modified LDL (mLDL), and oxidized
LDL (oxLDL). Notably, oxLDL promotes a powerful proinflammatory response by different cell
types, including the production of cell surface adhesion molecules and chemotactic factors by the
endothelium. OxLDL indirectly promotes the recruitment of circulating blood monocytes by binding
to the activated endothelium followed by trans-endothelial migration (TEM) into the sub-endothelial
intima, where the monocytes differentiate into macrophages. Here, the accumulation of oxLDL
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within the vascular wall further causes macrophage scavenger receptors (SRs) to bind and promote
oxLDL internalization, leading to the development of lipid-laden foam cells, i.e., the early stages of
atherosclerosis (atherogenesis) [4,5]. The vascular smooth muscle cell (VSMC) layer underlying the
intima can also respond to endothelial-derived factors secreted in response to oxLDL accumulation [6].
VSMCs also express SRs, which can enable oxLDL internalization and contribution to more lipid-laden
foam cell development, albeit to a lesser extent than macrophages [6].
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1.2. The Role of Atherosclerotic Plaque in CVD
The clinical consequences of atherosclerosis relate principally to ischaemia and acute
thrombo-occlusive events at the sites of plaque deposition. Thrombo-occlusive events in the majority of
cases result from plaque rupture [7]. The progression of atherosclerotic plaque from early asymptomatic
lesions to those which are high risk of rupture (i.e., vulnerable plaque) is well described [8,9]. Vulnerable
plaque is characterized by a large necrotic core with an overlying thin fibrous cap heavily infiltrated by
foamy macrophages [10]. Observational studies suggest that expansion of the necrotic core precedes
plaque rupture [10,11]. Inter-plaque haemorrhage has been identified as a critical step leading to
expansion of the necrotic core, where the accumulation of erythrocytes within the core leads to an
increased free cholesterol content and excessive macrophage infiltration [8]. Subsequent plaque rupture
exposes leukocytes, platelets, and circulating blood factors to underlying thrombogenic proteins,
e.g., Von Willebrand factor (VWF), leading to thrombus formation. Recent studies have highlighted
the phenomena of coronary artery plaque erosion (without rupture) and the formation of “white
thrombus” in patients with acute coronary syndrome (ACS) [12,13]. Plaque erosion has been previously
understood to account for one fifth of ACS; however, the most recent data suggests this has increased to
one third [14]. The working hypothesis to explain the rise of plaque erosion in ACS is that advances in
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lipid control have led to a shift in plaque morphology from the classical lipid-rich rupture-prone plaque
to a plaque that is low in lipid content and rich in proteoglycans, glycosaminoglycans, and VSMCs.
The mechanism of thrombus formation in eroded plaque differs from ruptured plaque. Briefly,
the activation and subsequent desquamation and apoptosis of endothelial cells due to disturbed flow
leads to the recruitment of neutrophils to the exposed basement membrane. Recruited neutrophils
congregate and in turn degranulate, leading to the formation of neutrophil extracellular traps (NETs).
NETs comprise mainly of myeloperoxidase and tissue factor amongst other extruded proteins, all
of which contribute to the formation of leucocyte-rich white thrombus by promoting leucocyte and
platelet recruitment [12–14]. The formation of NETs may also be promoted by circulating oxLDL as
shown in a recently published in vitro study [15]. In addition, the authors found that oxLDL and NETs
exerted synergistic proinflammatory effects on endothelial cells.
1.3. A Brief Introduction to SRs
SRs are defined as integral membrane proteins present at the cell surface, which typically bind
multiple ligands to promote clearance or harmful non-self or altered-self substance. SR activity usually
requires sensing and/or internalization of such substances, which ultimately leads to the elimination of
these substances [16]. In 1979, Goldstein, Brown and co-workers first described scavenger receptors
(SRs) whilst investigating how low-density lipoprotein (LDL) particles promote foam cell development
in atherosclerosis [17,18]. This led to the discovery that macrophages exhibit high-affinity binding
sites, which enable recognition of modified and negatively charged LDL particles, thus promoting
lipid particle internalization and subsequent formation of lipid-enriched foam cells [18]. Different
SRs have since been identified and categorized into 10 distinct classes based on primary structure
(Table 1) [19]. SRs are defined by common properties, such as the recognition and binding to ligands,
such as lipoprotein particles, phospholipids, apoptotic cells, carbohydrates, and cholesterol esters;
however, the primary consensus protein sequence within each class bears little or no homology to
other classes [19]. SRs are expressed largely in vascular and immune cells under physiological or
pathological conditions. Different immune cells express SRs, such as macrophages, which are linked to
the initiation and progression of atherosclerosis. The wide spectrum of SR expression has been linked
to pathological conditions, such as degenerative brain disease [20,21], malignancy [22], and systemic
inflammatory states, such as sepsis [23], rheumatoid arthritis [24], and renal vasculitis [25]. SR function
in regulating atherosclerosis is a major focus of research in CVD diagnosis and therapy. Current work
on SR regulation of atherosclerosis focuses largely on five SR classes: SR-A; SR-B (CD36 (cluster of
differentiation 36)); SR-E (lectin-like oxidized LDL receptor-1 (LOX-1)); SR-G (CXCL16); SR-J (receptor
for advanced glycation end-products (RAGEs)) (Figure 2). This review article aims to highlight
SR properties and functionality in the diagnosis and treatment of atherosclerosis linked to CVD as
summarized in Table 1.
Table 1. SR expression and function.











• Internalization of oxLDL
in atherosclerosis.
• Bacterial cell recognition in
innate immunity.
• Involved in beta-amyloid clearance in
the brain.
[20,29–32]
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• Renal tubular cells
• Podocytes
[33,34]
• Internalization of oxLDL
in atherosclerosis.
• Bacterial cell adhesion, internalization
and lysosomal sequestration.
• May participate in systemic
inflammation associated with sepsis.
[23,35,36]






• Myeloid dendritic cells
[37]











• Smooth muscle cells
• Platelets
[41]
• Internalization of oxLDL
in atherosclerosis.
• Bacterial and fungal cell recognition in
innate immunity.
• LOXIN (alternatively spliced form of
SR-E1) demonstrates no known
scavenger receptor activity but has
been shown to exert a dominant











• SR-F1 binds and internalizes oxLDL,
whilst formation of heterodimer with
SR-F2 suppresses oxLDL
binding activity.
• MEGF10 is involved in beta-amyloid




• Smooth muscle cells
[45,46]
• Adhesion of cells expressing the
CXCR6 receptor such as natural killer
T cells and polarized T helper cells.
• Internalization of oxLDL
in atherosclerosis.














• Internalization of oxLDL
in atherosclerosis.
• Bacterial cell recognition in
innate immunity.
• Binding of advanced glycation
end-products (AGEs).
• Potential role in the adhesion of
metastatic tumour cells to lymphatic
endothelial cells.
[50,52,53]
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• Amplification of immune and
inflammatory responses, cell mobility,
arterial injury, and atherogenesis via
sustained post-receptor signalling.
[57]
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of atherosclerosis. These molecules are potential biomarkers and therapeutic targets. Their structures
are represented in the sketches above. Abbreviations: N-terminus, N; C-terminus, C.
2. SRs as Biomarkers in CVD
The association of SRs with CVD status is well established, and multiple genes and isoforms
have been highlighted as potential marker for use in genetic screening for dis ase risk, or as
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diagnostic or prognostic biomarkers. Screening patients with a genetic predisposition to CVD has
potentially far-reaching benefits in disease prevention and early management. Polymorphisms in
genes encoding both CD36 and LOX-1 proteins have been associated with increased overall CVD
risk [58–60]. A single-nucleotide polymorphism (SNP) of the OLR1 (LOX-1, SR-E1) allele has been
shown to increase steady-state LOX-1 levels in vitro, suggesting that this polymorphism may contribute
to disease initiation and/or progression; OLR1 genotyping could be used for CVD risk stratification [60].
Moreover, a study of a group of 150 patients with acute myocardial infarction (MI) vs. a control group
of 103 healthy individuals identified SNPs in OLR1 associated with increased risk of MI [61]. Cohort
studies comparing healthy individuals and coronary artery disease (CAD) patient groups have shown
association between CD36 polymorphisms with increased lipid oxidation, CVD risk, and accelerated
development of CAD [58,59,62].
Much has been done to investigate the diagnostic value of quantifying SR levels in ACS. Circulating
concentrations of soluble SR-derived proteins in serum, and SR levels in specific immune cell types
have been studied. The use of an “SR-A index” quantifies monocyte SR-A expression in peripheral
blood smears from patients with CAD: this demonstrates that an increase in this SR-A index is
associated with altered atherosclerotic plaque status, leading to destabilization, i.e., disruption, fissure,
erosion [63]. Furthermore, such an SR-A index could be used to stratify plaque morphology, helping to
inform therapeutic strategies for CAD [64,65]. Similar studies show an association between circulating
monocyte CD36 levels and atheroma burden in CAD patients [66]. Overexpressed SR-A in macrophages
in atherosclerotic plaque has been targeted using SR-A-specific nanoparticles in an apolipoprotein-E
(APO-E)-null mouse model in order to identify vulnerable plaques using magnetic resonance imaging
with some success [67]. A similar study using CD36-targeted nanovesicles to quantify plaque burden
in low-density lipoprotein receptor (LDLR)-null mice showed similarly promising results [68]. The use
of SR-targeted probes in plaque identification, risk stratification, and quantification is an interesting
avenue of ongoing research.
Measuring biomarkers in serum is widely used in clinical settings to ACS diagnosis and
stratification for treatment [69]. Proteolytically derived soluble fragments or splice isoforms of
CD36, LOX-1, CXCL16, and RAGE are potential biomarkers for a range of CVD conditions, including
ACS, cardiac failure, cardiomyopathy, and carotid artery disease. A summary of studies investigating
the this potential application is seen in Table 2. Baseline serum levels of soluble CD36 (sCD36) have
been shown in three recent cohort studies to have no association with the development of CAD in
healthy subjects or plaque burden in known CAD patients [70,71]. Baseline levels of sCD36 were
also found to not be associated with carotid atherosclerosis in a recently performed cross-sectional
study [72]. In contrast, a recent case control study of patients with CAD found an association between
increased sLOX-1 levels and burden of CAD, compared with healthy controls [73]. A similar study of
metabolic syndrome patients found that baseline sLOX-1 levels were higher in patients with CAD,
implying a potential benefit in the measurement of baseline sLOX-1 levels in at-risk cohorts to risk
stratify for CAD development [74].
A small clinical study on 67 patients found that serum-soluble LOX-1 (sLOX-1) levels increased
significantly in ACS patients compared to a group of patients with stable angina pectoris [75]. A
combined index of serum sLOX-1 and cardiac troponin (cTn) levels improved diagnostic accuracy in
ACS compared with diagnostic tests carried out in isolation. The same study also found that measuring
sLOX-1 levels in ACS was a reliable test compared to a standard diagnosis of ACS [76]. A study on
107 patients undergoing coronary stenting found that measuring sLOX-1 levels was more informative
and accurate compared with cTn measurements in ACS diagnosis; a combined sLOX-1/cTn index
was a significantly better biomarker tool than measuring sLOX-1 levels alone [77]. The potential
ability of sLOX-1 in identifying the most severe acute coronary events was demonstrated in a recently
published study comparing levels of sLOX-1 in aspirated coronary thrombus from non-ST elevation
and ST-elevation myocardial infarction patients [78]. The studies that compare cTn and sLOX-1 as
biomarkers for ACS have consistently shown that sLOX-1 levels are raised earlier compared with
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cTn [76,77]. The hypothesis to explain this phenomenon is that sLOX-1 is released at the point of
plaque rupture and platelet activation during thrombus formation. Based on this hypothesis and the
findings from Lee et al. [78], there may be a role for sLOX-1 as a marker for coronary micro-thrombosis
peri-procedurally at the point of percutaneous coronary intervention; however, there are no data
currently to support this. Baseline sLOX-1 levels may also be of benefit as a prognostic biomarker
in stable CAD. A recently published study of 833 stable CAD patients found a positive correlation
between baseline sLOX-1 levels and major adverse cardiovascular events [79]. The relationship
between LOX-1 and myocardial reperfusion injury has been investigated in several mouse models
of myocardial ischaemia; however, this has not been further investigated in human studies. Mouse
models have demonstrated that LOX-1-null mice exhibit significantly less reperfusion injury and
significantly preserve cardiac function compared with wild-type mice [80,81]. In vitro and in vivo
heart failure models suggest sLOX-1 release by cardiac myocytes promotes apoptosis [82,83]. To
evaluate sLOX-1 as a biomarker for systolic heart failure, serum sLOX-1 levels were measured in
55 patients with systolic heart failure and compared to a control group of 25 individuals. Serum
sLOX-1 levels were found to negatively correlate with left ventricular ejection fraction, particularly
in patients with ischemia-related aetiology [84]. The relationship between LOX-1 and C-reactive
protein (CRP) in atherogenesis and their role as biomarkers for cardiovascular events is an area of
ongoing interest. CRP is a widely used biomarker for inflammation, which is also highly predictive of
recurrent cardiovascular events [85]. In vitro studies have demonstrated that CRP induces endothelial
cell LOX-1 expression, leading to increased monocyte adhesion and oxLDL uptake [86]. The release
of sLOX-1 from monocytes is stimulated by incubation CRP, via the activation of tumour necrosis
factor-α in vitro [87]. These studies demonstrate the synergistic effects of CRP and LOX-1 and their
potential for use as biomarkers in tandem. The evidence supporting the potential use of sLOX-1 as a
biomarker for stroke is mounting but is not as significant compared with CAD and ACS. Multiple small
cohort studies comparing serum sLOX-1 levels between patients presenting with acute stroke and
controls found that serum sLOX-1 levels were significantly raised in ischaemic stroke and haemorrhagic
stroke, and that higher sLOX-1 levels independently predicted poorer neurological outcomes [88–90].
A recently published prospective population study of 4703 participants found that higher baseline
sLOX-1 levels were associated with an increased incidence of ischaemic stroke over a 16.5-year mean
follow-up [91]. In participants requiring carotid endarterectomy (n = 202), higher baseline sLOX-1
levels were associated with an increased incidence of recurrent ischaemic events post-operatively.
The source of increased sLOX-1 levels and the timing of sampling in acute stroke are areas of controversy.
Most studies have hypothesized that sLOX-1 is released from the offending atherosclerotic plaque;
however, the contribution of cerebral ischaemia to sLOX-1 levels is unknown. Skarpengland et al.
recently examined carotid plaque OLR1 gene expression and plasma sLOX-1 levels in patients referred
for carotid endarterectomy [92]. Predictably, circulating sLOX-1 levels and arterial OLR1 expression
were increased in patients with carotid plaque compared with healthy controls. Interestingly, sLOX-1
levels were comparably increased in patients with thrombotic ischaemic stroke and embolic stroke
secondary to atrial fibrillation, raising the possibility that the ischaemic event may contribute to sLOX-1
release. The embolic stroke patients must have harboured a degree of carotid plaque, however, to
warrant a referral for carotid endarterectomy.
The SR member, CXCL16, is a membrane-bound chemokine, which binds oxLDL and promotes
proinflammatory responses linked to atherosclerosis development [93]. Serum-soluble CXCL16
(sCXCL16) has been evaluated as a potential biomarker in CAD, inflammatory cardiomyopathy,
and carotid artery disease. In 118 patients presenting with an acute ischaemic stroke, serum sCXCL16
levels were significantly higher in patients with vulnerable carotid plaques, a higher degree of luminal
stenosis, and increased intimal layer thickness [94]. Other clinical studies have also shown that
measuring serum sCXCL16 concentration can improve diagnostic accuracy when combined with cTn
and sLOX-1 in ACS, and that may be of benefit in with type 2 diabetes mellitus (T2DM) patients [49,95].
As a prognostic biomarker, a study of 1351 ACS patients found that a single measurement of serum
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sCXCL16 within 24 h of hospital admission indicated that higher sCXL16 levels increased risk of
longer term mortality, suggesting that CXCL16 may be part of sustained proatherogenic inflammatory
response in this patient cohort [96]. A recently published cohort study of 5142 ACS patients found that
increasing serial CXCL16 levels were associated with composite adverse clinical outcomes and that the
CXCL16 level on admission was independently associated with cardiovascular death [97]. A large
cohort study of healthy individuals performed in Norway compared baseline CXCL16 levels between
those who developed myocardial infarction and those who did not over the trial period of 11 years [98].
Increased baseline CXCL16 levels were associated with increased risk of myocardial infarction, further
strengthening the case for CXCL16 as a prognostic biomarker for CAD. CXCL16 has also been
proposed as a prognostic biomarker in inflammatory cardiomyopathy and heart failure. In 174 patients
with heart failure, myocardial biopsy samples stained for CXCL16 showed significantly enhanced
expression in inflammatory cardiomyopathy compared with non-inflammatory cardiomyopathy [99].
The same study found that increased CXCL16 expression was an independent predictor of death in
both inflammatory and non-inflammatory cardiomyopathy patients.
Table 2. SRs as biomarkers in CVD.
Disease State SR Biomarker Human Studies
CAD/ACS
SR-A
• SR-A index (monocyte SR-A expression in peripheral blood
film) associated with advanced plaque morphology [63–65].
• SR-A-targeted probes used for plaque imaging [67].
SR-B
• Monocyte CD36 expression associated with increased
atheroma burden in CAD patients [66].
• CD36-targeted probes used for plaque imaging [68].
• Baseline sCD36 not associated with CAD development or
plaque burden [70,71].
SR-E
• Raised serum levels of sLOX-1 used as a diagnostic biomarker
in ACS [75–77].
• sLOX-1 levels combined with troponin levels provide more
diagnostic accuracy compared with either in isolation [76,77].
• Raised sLOX-1 levels correlate with incidence of major adverse
cardiovascular events in stable CAD [79].
SR-G
• sCXCL16 levels improve diagnostic accuracy in ACS when
combined with troponin/LOX-1 [49,95].
• sCXCL16 levels are associated with increased adverse events
and mortality in ACS [96,97].
• Baseline sCXCL16 levels associated with increased risk of ACS
in non-CAD patients [98].
SR-J
• Due to conflicting reports, the potential use of sRAGE as a
biomarker for ACS remains controversial.
Cardiomyopathy
SR-E
• sLOX-1 levels negatively correlate with left ventricular ejection
fraction [84].
SR-G
• Increased sCXCL16 levels independently predict mortality in
inflammatory and non-inflammatory cardiomyopathy [99].
• Enhanced CXCL16 expression in cardiac myocytes in
inflammatory cardiomyopathy [99].




• sLOX-1 levels increased in ischaemic and haemorrhagic
stroke [88,89].
• Increased baseline sLOX-1 levels associated with increased
incidence of ischaemic stroke and secondary ischaemic events
post-carotid intervention [91].
SR-G
• Increased sCXCL16 associated with more advanced carotid
lesions in patients presenting with ischaemic stroke [94].
The class J members include the receptor for advanced glycation end-products (RAGEs), which
can undergo proteolytic cleavage to release a soluble fragment (sRAGE) present in extracellular fluids,
including blood. sRAGE has been proposed as a novel diagnostic and prognostic biomarker in CVD;
however, conflicting data has led to controversy. Multiple studies have found that increased serum
sRAGE levels are predictive of serious clinical events in CAD and cardiovascular conditions [100–103].
The relationship is not entirely straightforward: a computed tomography angiography study of sRAGE
levels in 127 consecutive patients with non-acute CAD found that higher sRAGE levels were inversely
proportional to overall plaque burden [104]. Another study of 328 non-diabetic male patients found the
same inverse relationship [105]. As a biomarker for the diagnosis of ACS, similar controversy exists.
While numerous studies have found significantly higher levels of sRAGE in ACS compared with
controls, and a positive correlation between sRAGE and troponin levels in ACS patients, conflicting
studies report no significant differences [106]. The most recent study of sRAGE in ACS by Larsen et
al. assessed the utility of sRAGE as a prognostic biomarker post-ACS and found that while baseline
sRAGE was associated with greater risk of major adverse cardiac events post-ACS, sRAGE levels
recorded at 6 weeks post-ACS were inversely related to the rate of recurrent ischaemic events [107].
The impact of diabetes mellitus on the diagnostic utility of sRAGE in ACS has been demonstrated by
multiple studies to be non-significant [106].
3. SRs as Therapeutic Targets in CVD
3.1. Current Therapy
Owing to a central role for SR functionality in atherosclerotic plaque development and progression,
targeting SRs is of great interest in CVD therapy. Multiple therapeutic avenues have been explored,
including repurposing clinically approved drugs, herbal medicines, and emerging clinical modalities,
such as gene therapy and nanoparticle administration. One well-established therapeutic regime
worldwide is the long-term use of small-molecule inhibitors of hydroxymethylglutaryl-coenzyme
A (HMG Co-A) reductase, commonly known as statins. These drugs are cholesterol-lowering
agents that are well accepted in reducing the atherosclerosis burden and risk of CVD [108]. Statins
not only reduce total serum cholesterol but also exhibit pleiotropic effects on the vascular wall,
including improved endothelial function, a reduction in vascular inflammation, and enhanced plaque
stability [109]. The effect of statin therapy on SR function is not yet understood. An in vitro study on a
THP-1 human monocyte cell line found that atorvastatin caused dose-dependent attenuation of an
oxLDL-stimulated increase in SR-A and monocyte chemoattractant protein-1 (MCP-1) levels [110].
Atorvastatin also reduced lipid-laden foam cell development, indicating that cholesterol levels and
plaque development are functionally linked. Another compound, pitavastatin, caused a significant
increase in SR-B1 in murine and human macrophages: this SR has been implicated as an anti-atherogenic
factor [111,112]. Statins also promote endothelial-derived nitric oxide (NO) levels by activation of
SR-B1 and downstream signalling events [112]. Various statins have been found to downregulate CD36
expression in VSMCs in vitro and in circulating monocytes in human subjects [113]. A recent APO-E-null
mouse model of atherosclerosis found that simvastatin administration reduced CD36 expression as
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well as atherosclerosis and inflammatory signalling compared with controls [114]. Statins have been
shown to downregulate LOX-1 levels and reduce serum sLOX-1 levels, thus reducing the cellular
capacity to sense oxLDL, and activate proatherogenic signalling to downstream pathways [115,116].
Reduced LOX-1 levels caused by statin therapy also has additional anti-atherogenic properties, such as
increased NO levels, and downregulation of adhesion molecules [117,118]. The importance of the link
between LOX-1 and statins in arterial disease is further highlighted in a cohort study of 751 patients
with hypercholesterolaemia receiving statin therapy: OLR1 (LOX-1) polymorphisms are linked to
circulating LDL levels and risk of CVD [119].
Statin administration may also affect proatherogenic RAGE levels. Simvastatin treatment
of diabetic patients causes the downregulation of RAGE levels in atherosclerotic plaques [120].
Atorvastatin treatment increases sRAGE levels in vitro. Here, sRAGE could act as a decoy to inhibit
proatherogenic effects of advanced glycation end-product (AGE) species [121]. One issue is the
structurally different statins have similar effects on SR activity and function; this has not been resolved
at present. There are notable differences between the therapeutic effects of atorvastatin, which is less
noticeable when pravastatin is used.
Monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are relatively
novel LDL-lowering agents, which have recently been approved for clinical use. PCSK9 is a protease
required for the degradation of the LDLR [122]. PCSK9 inhibitors work by inhibiting PCSK9–LDLR
interaction, leading to decreased LDLR degradation and ultimately a reduction in serum LDL
cholesterol. Studies by Ding et al. investigating the possibility of interactions between PCSK9 and
LOX-1 suggest that cross-talk between PCSK9 and LOX-1 exists in the form of positive feedback [123].
The authors demonstrate LOX-1 ablation in cellular and transgenic mouse experiments results in
reduced PCSK9 expression and vice versa with PCSK9 ablation. The activation of the PCSK9–LOX-1
axis has also been shown to be mediated by altered ROS generation at sites of shear stress [124].
The effects of monoclonal PCSK9 inhibitors on LOX-1 expression in humans is not known; however,
it is conceivable that LOX-1 downregulation resulting from PCSK9 inhibition could be providing
additional anti-atherogenic benefit.
Peroxisome proliferator-activated receptor-γ (PPAR-γ) exhibits anti-inflammatory and antidiabetic
properties. Pioglitazone is a PPAR-γ agonist, which is commonly prescribed as a glucose-lowering
agent for T2DM patients. Analysis of human and animal models treated with pioglitazone has effects
on SR levels and function in the context of diabetes and metabolic syndrome. In a study of 30 patients
with polycystic ovarian syndrome (PCOS) combined with either increased fasting glucose or obesity,
serum sCD36 levels were significantly raised compared to healthy controls (n = 14) [125]. Furthermore,
pioglitazone treatment significantly reduced circulating sCD36 and CRP levels whilst improving insulin
sensitivity. This strengthens an association between sCD36 and insulin resistance in PCOS. In this
cohort, pioglitazone treatment may have an added benefit of reducing risk of CVD. A different study
on diabetic APOE-null mice subjected to pioglitazone treatment observed attenuation of atherosclerosis
via RAGE-linked signalling events [126]. These studies showed that pioglitazone administration
reduced atherosclerotic plaque burden in coronary arteries and inhibited RAGE expression in arterial
and vascular smooth muscle cells.
Other clinically approved drugs that modulate LOX-1 expression and/or function include
ursolic acid, histamine, spironolactone, and angiotensin-converting enzyme (ACE) inhibitors.
Ursolic acid inhibits LOX-1 expression in vitro and significantly reduces both LOX-1 expression
and atherosclerotic plaque burden in arteries of APOE-null mice [127]. Similar outcomes were
observed using the same models treated with histamine [128]. Antihypertensive medications, such
as spironolactone (potassium-sparing diuretic) and losartan (angiotensin II receptor inhibitor), have
been shown to downregulate LOX-1 levels and functionality, thus showing wider benefits for targeting
atherosclerosis [129,130]. Nifedipine, a calcium channel blocker used commonly in hypertension, has
been found to reduce CD36 expression and lipid internalization in macrophages in vitro [113].
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3.2. Novel Therapeutics
Deletion of a functional SR-A locus in transgenic mouse models causes a significant reduction in
atherosclerosis plaque burden in the aorta, stimulating many groups to search for novel therapeutics
or inhibitors that target SR-A function or activity [131]. Recent work investigating the role of
SR-A activation in neutrophils and NET formation has found that NET release may be triggered
by SR-A activation by reactive oxygen species (ROS) [132]. The role of NETs in plaque erosion
and thrombo-occlusive complications of CVD is becoming more prominent and the role of SR-A
targeting in this area is a potential area for future studies. Certain amphiphilic macromolecules (AMs)
that exhibit selective binding to SR-A have shown promise in attenuating atherosclerosis [133,134].
SR-A-specific AMs not only reduce oxLDL binding and uptake in human embryonic kidney cells but
also inhibit proinflammatory signalling in activated THP-1 monocytes [134]. Using rat models, this
study also showed a reduction in intimal cholesterol accumulation and macrophage retention under
proatherogenic conditions [134]. Higher serum levels of the anti-inflammatory cytokine interleukin-10
(IL-10) were associated with superior outcomes in ACS patients, but this was not fully understood at
that time [135,136]. Since these studies, it has been found that IL-10 addition reduces oxLDL uptake
and downregulates SR-A levels in activated THP-1 monocytes [137]. Such work provides further
support for IL-10 as a therapeutic strategy aimed at SR-A for CVD, particularly in ACS.
Macrophage SR-A expression in macrophages is downregulated by treatment with intermedin, a
novel member of the calcitonin gene-related peptide family: intermedin attenuates atherosclerosis
plaque burden in APOE-null mice [138]. Intermedin is implicated in vascular homeostasis by reducing
calcium deposition in atherosclerotic plaques [139]. Intermedin treatment caused increased expression
of the phosphatase and tensin homolog (PTEN) whilst SR-A levels were reduced, further supporting
intermedin use in CVD therapy [139]. SR-A is also a potential target in diabetic nephropathy, although
no therapeutics are forthcoming for such therapy. SR-A-null mice subjected to streptozotocin-induced
diabetes mellitus exhibit significant changes in markers of nephropathy, such as albuminuria, glomerular
hypertrophy, mesangial matrix expansion, and parenchymal macrophage infiltration with increased
levels of transforming growth factor-β [140].
Using RNA interference (RNAi) to downregulate SR-A and CD36 levels is effective in reducing
oxLDL uptake in vitro and atherosclerotic load in vivo when either receptor is targeted in isolation;
however, when both receptors are simultaneously targeted, there is no change compared to controls [141].
One likelihood is that downregulation of either SR-A or CD36 alone causes a reciprocal upregulation of
the other; SR crosstalk could explain why inhibition of both receptors is less effective than targeting a
single receptor. Further studies also indicate conflicting conclusions in targeting both SR-A and CD36
together. Monoclonal antibody-mediated targeting of either SR-A or CD36 separately reduces foam cell
formation in vitro [142], but simultaneously targeting both receptors in this context was not studied.
Double knockout of SR-A and CD36 in APO-E-null mice did not reduce aortic root atherosclerosis
compared with APOE-null mice; however, the authors did not study SR-A- or CD36-null mice in
isolation [143]. Single and double knockout mouse lines have been studied elsewhere, with findings
that CD36 ablation significantly reduced aortic atherosclerotic plaque burden; however, SR-A-null
mice were less effective in isolation, and SR-A/CD36 double-null animals showed comparable efficacy
to CD36-null mice [144]. A recent study of insulin sensitivity in a mouse model of obesity found that
SR-A knockout exacerbated insulin resistance compared with wildtype mice [145]. Interestingly, in a
similar study, CD36 knockout provided protective effects against insulin resistance [146]. These studies
highlight the importance of studying the off-target effects of SR targeting as each class of receptor is
likely to exhibit unique and potentially opposing tissue-specific functions.
CD36 is a multi-ligand multifunctional scavenger receptor, which plays a complex role in CVD
and cerebrovascular disease states [147]. CD36 exhibits both proatherogenic and anti-angiogenic
properties in vitro and in vivo [148,149] and there is an emerging understanding that there may be an
“optimal protective window” of CD36 expression [150]. CD36-null mice display a significant increase
in angiogenesis and re-vascularization after acute stroke [151]. Treatment with a cell-permeable
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antioxidant peptide (SS31) reduces cerebral oxidative stress and infarct size in a mice subjected to
transient middle cerebral artery occlusion, but this effect was absent in the CD36-null group [152],
indicating that the therapeutic effects of SS31 is occurring via a CD36-regulated pathway. Nanoparticles,
such as AMs and nanovesicles, have been identified, which bind to CD36 and inhibit oxLDL uptake
in vitro [68,153]. CD36-targeted liposome-like nanovesicles show impressive binding affinities to
CD36 in vitro and in vivo in atherosclerotic LDLR-null mice. CD36-targeted nanovesicles thus have
potential for reducing atherosclerosis. Synthetic protein ligands that bind CD36, such as EP80317,
have been shown to reduce oxLDL uptake by macrophages and atherosclerotic plaque burden in
APOE-null mice [154]. Furthermore, EP80317 administration promotes reverse cholesterol transport in
macrophages; gut receptors, such as LXRα and NPC1L1, further facilitate cholesterol removal through
faecal excretion [155]. The administration of ectopic adipokines to ameliorate atherosclerosis by CD36
modulation has been recently investigated by Wang et al. [156]. The authors found that administration
of C1q/tumour necrosis factor-related protein 13 (CTRP13) reduced CD36 expression in vitro and
significantly reduced aortic atherosclerosis in vivo, thus defining a potential novel therapeutic in
atherosclerosis by SR modulation.
LOX-1 targeting in atherosclerosis attracts much interest, due to its proatherogenic properties [157].
In vitro studies show that blocking LOX-1 reduces the proapoptotic effects of oxLDL; transgenic animal
studies indicate that OLR1/LDLR double-null mice exhibit reduced atherosclerotic plaque burden
in coronary arteries [158,159]. Administration of anti-LOX-1 antibody in animal models causes a
significant reduction in arterial pathologies characteristic of neointimal hyperplasia and MI [160,161].
Furthermore, anti-LOX-1 antibody administration in a hypertensive rat model causes reduction of
lipid deposition in mesenteric arteries; such treatment also attenuates renal vascular fibrosis in an
obese diabetic hypertensive rat model [162,163].
Studies on microRNAs (miRNAs) linked to atherosclerosis and CVD is a relatively new but
increasing area of interest. These miRNAs are usually tissue-specific relatively small (∼22 bases),
non-protein coding RNAs, which bind one or more protein-coding mRNAs to regulate protein
expression: miRNAs are implicated in many pathological processes, including atherosclerosis [164].
Dai and colleagues used bioinformatics to identify miRNA-98 as a LOX-1-specific agent and showed
that miRNA-98 administration reduced lipid accumulation in vitro; this treatment also reduced LOX-1
expression and aortic plaque burden in APOE-null mice [165]. A similar study showed that miRNA
let-7g-mediated targeting of LOX-1 attenuated the development of atherosclerosis [166]. As many
miRNAs bind multiple mRNA species, off-target effects of miRNA therapy is a serious concern; however,
LOX-1-specific miRNA therapy did not raise toxicity issues [165]. Small interfering RNAs (siRNAs),
which target the LOX-1 mRNA and knockdown protein expression, can also inhibit LOX-1-regulated
pathways in vitro [167]. Although initial studies are promising [167], further evaluation in animal
models is needed to better evaluate such treatments to attenuate atherosclerosis and plaque burden.
Similar to the use of miRNAs, antibodies, and synthetic proteins to target LOX-1, careful evaluation of
off-target effects and absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters
is needed before effective therapies can be implemented [168].
The three-dimensional structure of the LOX-1 extracellular domain has been determined using
a combination of crystallography and NMR [169]. This 3-D model for LOX-1 was used to screen
chemical libraries to identify new molecules that block LOX-1 function; two lead compounds could
reduce oxLDL uptake and monocyte adhesion to endothelial cells [170]. Chemical compounds
with cell- and tissue-penetrating properties have substantial advantages over antibody or synthetic
protein-based therapies; however, such compounds require careful evaluation of ADMET parameters
in whole animal models. Single-chain variable fragment (scFv) antibodies targeting LOX-1 have
been recently reported [171]. These scFvs exhibit specific binding affinity, enhanced bio-distribution,
and low immunogenicity compared with humanized monoclonal antibodies, whilst being substantially
cheaper to produce using bacterial expression systems. LOX-1-specific scFvs are in the early stages
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of development and ongoing studies are aiming to improve the binding affinity, thermostability,
and serum half-life, and using multimerization techniques [172,173].
The relationship between CXCL16 and atherogenesis is less defined compared with SR-A, CD36,
and LOX-1. A sCXCL16 isoform is a potential biomarker for CAD, and membrane-bound CXCL16
is highly expressed in carotid and coronary artery atheromas [174]. Hofnagel and co-workers found
that CXCL16 is expressed primarily in the endothelium at sites predisposed to atherosclerosis in
the rabbit aorta; furthermore, anti-CXCL16 antibody treatment of primary human endothelial cells
caused a significant reduction in endothelial-monocyte adhesion [175]. However, there is still a need
to demonstrate that anti-CXCL16 monoclonal antibody therapy has efficacy in an animal model of
atherosclerosis. Interestingly, LDLR/CXCL16 double-null transgenic mice displayed an increased
atherosclerotic plaque burden compared to LDLR-null mice [93]; this work suggests that the CXCL16
locus is anti-atherogenic, contradicting previous studies.
AGEs have been suggested to be proatherogenic, especially in the context of atherosclerosis in
diabetes mellitus patients. Inhibition in biochemical pathways that cause the production of AGEs using
agents, such as aminoguanidine-HCl, which inhibits chemical crosslinking, can produce beneficial
cardiovascular outcomes in vivo [176]. The binding and cellular uptake of oxLDL by RAGE is promoted
by AGEs; this proatherogenic effect can be blocked by anti-RAGE treatment [177]. RNAi to target
RAGE expression reduced endothelial-monocyte adhesion, and improved CVD-related outcomes [178].
Diabetic transgenic mice carrying the APOE/RAGE double-null genotype displayed reduced leucocyte
adhesion, expression of proinflammatory mediators, and a statistically non-significant decrease in
reduction in aortic atherosclerotic plaque burden [179]. Interestingly, administration of recombinant
sRAGE in diabetic APOE-null mice suppresses atherosclerosis whilst having little or no effect on
plasma lipids or serum glucose levels [180]. One hypothesis is that sRAGE acts as a circulating soluble
“AGE sponge”, thus downregulating membrane-bound RAGE expression in vascular tissues, further
reducing proatherogenic signalling and cellular responses [180].
Novel drug delivery systems, such as nanocarriers and nanovesicles, have been employed with
some success in SR targeting in atherosclerosis [68,153]. The ideal delivery system is one that exhibits
immunological inertness and non-cytotoxicity, high tissue permeability and specificity, excellent
biodistribution, and adequate half-life in the circulation. A recently published study evaluating the use
of M2 macrophage-derived exosomes as a novel drug delivery system in atherosclerosis describes their
ability to target areas of atherosclerosis by inflammation-tropism via the expression of surface-bonded
chemokine receptors [181]. Atherosclerosis-targeting drug delivery systems may have an important
future role in the development of SR-targeted therapies.
4. Conclusions
SRs are a multi-ligand receptor super-group defined by the ability to recognize modified lipid
particles; each class has a defined consensus sequence, which is usually unrelated to other classes. One
common feature of this diverse group of proteins is the ability to bind potentially harmful substances to
mediate clearance from circulation. Many SRs are linked to atherosclerosis, which is the main pathway
involved in the development of CVD. The current view is that the main SRs involved in CVD are SR-A,
CD36, LOX-1, CXCL16, and RAGE. Monitoring serum levels of soluble SRs, alongside cardiac troponins,
in better diagnosis of MI and ACS is a potential prognostic tool. Current cholesterol-lowering therapies,
e.g., statin treatment, have been also found to modulate SR expression and downstream signalling,
suggesting wider implications of SR function linked to cholesterol metabolism. So far, numerous
approaches for targeting SRs, including gene therapy, monoclonal antibodies, and nanoparticles, have
shown differing levels of success in reducing CVD. A major issue is that SR studies have so far not
progressed beyond animal models; only SR biomarker assessments in human patients have been
carried out. We concur that the future application of SR-linked tools and therapies will play a central
role in the diagnosis, management, and treatment of arterial pathologies, such as CVD.
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5. Future Perspectives
SRs are attractive molecular targets in the development of targeted therapy for atherosclerosis.
While the results from in vitro and in vivo models are promising, SR receptor modulation in humans has
not been investigated. Given that SRs expression is widespread in multiple organ systems, the concept
of systemic SR modulation should be considered with caution as there is a significant potential for
off-target effects and reciprocal upregulation of SRs from the other classes. Local delivery of SR
modulators utilizing novel delivery systems, such as exosomes and other nanocarrier technologies,
may play an important role in translating SR-targeting agents to a clinical setting.
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